Vimarsana
Biggest News Aggregation in the World

Page 31 - Fda Approval News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Fda Approval. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Fda Approval Today - Breaking & Trending Today

FDA Approves Elranatamab for Relapsed or Refractory Multiple Myeloma - Vimarsana News

FDA Approves Elranatamab for Relapsed or Refractory Multiple Myeloma

The FDA has granted accelerated approval to elranatamab-bcmm (Elrexfio) for the treatment of adult patients with relapsed or refractory multiple myeloma who have previously received at least 4 lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.

Source: ajmc.com
IntelGenx Technologies Corp. (PNK:IGXT) Q2 2023 Earnings Call Transcript - Vimarsana News

IntelGenx Technologies Corp. (PNK:IGXT) Q2 2023 Earnings Call Transcript

IntelGenx Technologies Corp. (IGXT) Q2 2023 Earnings Call Transcript August 14, 2023 Operator: Greetings. And welcome to the IntelGenx Second Quarter 2023 Financial Results Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] Please note, this conference is being recorded. I will […]

Source: yahoo.com
Eyenovia, Inc. (NASDAQ:EYEN) Q2 2023 Earnings Call Transcript - Vimarsana News

Eyenovia, Inc. (NASDAQ:EYEN) Q2 2023 Earnings Call Transcript

Eyenovia, Inc. (NASDAQ:EYEN) Q2 2023 Earnings Call Transcript August 13, 2023 Operator: Greetings. Welcome to the Eyenovia Second Quarter 2023 Earnings Call. [Operator Instructions] As a reminder, this conference is being recorded. At this time, I would like to hand the call over to your moderator, Eric Ribner of Investor Relations. Thank you. You may […]

Source: yahoo.com
Gamida Sees Strong Start For Omisirge Launch, To Report Non-Hodgkin Lymphoma Trial Data In Q1 - Vimarsana News

Gamida Sees Strong Start For Omisirge Launch, To Report Non-Hodgkin Lymphoma Trial Data In Q1

Gamida Cell Ltd. (GMDA), which recently secured FDA approval for its cell therapy Omisirge, on Monday, said that it is seeing high interest from transplant centers, exceeding its expectations.

FDA Approves Niraparib Plus Abiraterone Acetate for BRCA+ mCRPC - Vimarsana News

FDA Approves Niraparib Plus Abiraterone Acetate for BRCA+ mCRPC

The FDA has approved niraparib plus abiraterone acetate, given with prednisone, for the treatment of adult patients with deleterious or suspected deleterious BRCA-positive, metastatic castration-resistant prostate cancer, as detected by an FDA-approved test.